Pyridoxine

Pyridoxine

SCHEMBL5364587

CC(O)C(=O)O.Cc1ncc(CO)c(CO)c1O

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1

The experimentally established mechanism targets of Pyridoxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 known ✓ Q13547 2/20 0.40
KDM4E B2RXH2 4/20 0.73
ALDH1A1 P00352 4/20 0.73
HPGD P15428 4/20 0.73
HSD17B10 Q99714 1/20 0.73
LMNA P02545 4/20 0.58
PDXK O00764 3/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
AOX1 Q06278 1/20 0.49
TRIM24 O15164 1/20 0.48
TRIM33 Q9UPN9 1/20 0.48
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
HIF1A Q16665 1/20 0.45
GAA P10253 2/20 0.44
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridoxine SCHEMBL23647341 0.87 KDM4E (0.83) KDM4EALDH1A1HPGDHSD17B10LMNA
Pyridoxine SCHEMBL405402 0.87 KDM4E (0.83) KDM4EALDH1A1HPGDHSD17B10LMNA
Pyridoxine SCHEMBL6520345 0.86 KDM4E (0.65) KDM4EALDH1A1HPGDHSD17B10LMNA
Pyridoxine SCHEMBL5351112 0.86 KDM4E (0.65) KDM4EALDH1A1HPGDHSD17B10LMNA
Pyridoxine SCHEMBL9168156 0.86 KDM4E (0.80) KDM4EALDH1A1HPGDHSD17B10LMNA
Pyridoxine SCHEMBL15486045 0.86 KDM4E (0.80) KDM4EALDH1A1HPGDHSD17B10LMNA
Pyridoxine SCHEMBL5346680 0.86 KDM4E (0.80) KDM4EALDH1A1HPGDHSD17B10LMNA
Pyridoxine SCHEMBL3506 0.85 HPGD (1.00) KDM4EALDH1A1HPGDHSD17B10LMNA
Pyridoxine SCHEMBL2322958 0.85 HPGD (1.00) KDM4EALDH1A1HPGDHSD17B10LMNA
Pyridoxine SCHEMBL30877002 0.85 HPGD (1.00) KDM4EALDH1A1HPGDHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170360687-A1 SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF L'OREAL (FR) 2017-12-21 US claimed
EP-3236922-A1 SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF L'OREAL (FR) 2017-11-01 EP claimed
WO-2016102702-A1 SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF L'OREAL (FR) 2016-06-30 WO claimed
US-20060147508-A1 Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes BIODERM RESEARCH (US) 2006-07-06 US claimed
US-20040228884-A1 Ion-pair delivery system for cosmetic and pharmaceutical compositions GUPTA SHYAM K (US) 2004-11-18 US claimed
US-20040156873-A1 Topically Bioavailable Acne and Rosacea Treatment Compositions GUPTA SHYAM K (US) 2004-08-12 US claimed
US-20040092482-A1 Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions GUPTA SHYAM K (US) 2004-05-13 US claimed
US-20170360687-A1 SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF L'OREAL (FR) 2017-12-21 US disclosed
EP-3236922-A1 SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF L'OREAL (FR) 2017-11-01 EP disclosed
WO-2016102702-A1 SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF L'OREAL (FR) 2016-06-30 WO disclosed
US-7179477-B2 Cosmetic dermabrasion treatment system GUPTA SHYAM K 2007-02-20 US disclosed
US-20060147508-A1 Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes BIODERM RESEARCH (US) 2006-07-06 US disclosed
WO-2006023710-A2 COSMETIC OR PHARMACEUTICAL COMPOSITION FOR SKIN CARE INFINITY2 HEALTH SCIENCES, INC. (US) 2006-03-02 WO disclosed
US-20060039887-A1 Cosmetic or pharmaceutical composition for skin care INFINITY2 HEALTH SCIENCES, INC. 2006-02-23 US disclosed
US-20050037038-A1 Cosmetic Dermabrasion Treatment System GUPTA SHYAM K (US) 2005-02-17 US disclosed
US-20040228884-A1 Ion-pair delivery system for cosmetic and pharmaceutical compositions GUPTA SHYAM K (US) 2004-11-18 US disclosed
US-20040092482-A1 Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions GUPTA SHYAM K (US) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092482-A1 Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions CUTA, HIRA, HARS1 HDAC1 3070/4885KDM4E 2354/4885ALDH1A1 1928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.